A prospective evaluation of the role of Vascular Endothelial Growth Factor (VEGF) and the immune system in stage III/IV melanoma

Nicole Marie Agostino, Christine Saraceni, Hope Kincaid, Wenjing Shi, Wendy Kay Nevala, Svetomir Nenad Markovic, Suresh G. Nair

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: The immune system and vascular endothelial growth factor (VEGF) may be influential in melanoma behavior. We performed a prospective, exploratory analysis in 10 stage III and 22 stage IV melanoma patients to observe factors influencing outcomes. Patients and methods: Patients accrued during 2010 and 2011 were treated according to standard protocols for disease stage. We analyzed selected biomarkers for predictive patterns of clinical response. Survival outcomes were calculated using Kaplan-Meier curves. Results: Baseline LDH was negatively correlated with length of survival and positively correlated to baseline VEGF in stage IV melanoma patients. We found a positive correlation between peripheral blood Treg concentrations and baseline VEGF in stage IV patients. No stage III patients died during the study period; median survival for stage IV patients was 48 months using a Kaplan-Meier survival curve, which illustrates the enrichment for exceptional stage IV survivors. Six stage IV patients remain disease free, including 4 of the 10 patients who received IL-2 +/− metastatectomy. Conclusions: Recent advances in immunotherapy have demonstrated durable therapeutic responses which may favorably impact survival. Examining T-cell characteristics of metastatic melanoma patients may gain further insight into underlying immunomodulation mechanisms to guide improved therapies.

Original languageEnglish (US)
JournalSpringerPlus
Volume4
Issue number1
DOIs
StatePublished - Dec 1 2015

Fingerprint

Vascular Endothelial Growth Factor A
Immune System
Melanoma
Survival
Immunomodulation
Kaplan-Meier Estimate
Immunotherapy
Interleukin-2
Survivors
Biomarkers
T-Lymphocytes
Therapeutics

Keywords

  • Biomarkers
  • CD4+/CD8+ ratio
  • LDH
  • Melanoma
  • Stage IV
  • TH1/TH2 ratio
  • Tregs
  • VEGF

ASJC Scopus subject areas

  • General

Cite this

A prospective evaluation of the role of Vascular Endothelial Growth Factor (VEGF) and the immune system in stage III/IV melanoma. / Agostino, Nicole Marie; Saraceni, Christine; Kincaid, Hope; Shi, Wenjing; Nevala, Wendy Kay; Markovic, Svetomir Nenad; Nair, Suresh G.

In: SpringerPlus, Vol. 4, No. 1, 01.12.2015.

Research output: Contribution to journalArticle

Agostino, Nicole Marie ; Saraceni, Christine ; Kincaid, Hope ; Shi, Wenjing ; Nevala, Wendy Kay ; Markovic, Svetomir Nenad ; Nair, Suresh G. / A prospective evaluation of the role of Vascular Endothelial Growth Factor (VEGF) and the immune system in stage III/IV melanoma. In: SpringerPlus. 2015 ; Vol. 4, No. 1.
@article{e624cf41df844378929e2b4db838ca9f,
title = "A prospective evaluation of the role of Vascular Endothelial Growth Factor (VEGF) and the immune system in stage III/IV melanoma",
abstract = "Background: The immune system and vascular endothelial growth factor (VEGF) may be influential in melanoma behavior. We performed a prospective, exploratory analysis in 10 stage III and 22 stage IV melanoma patients to observe factors influencing outcomes. Patients and methods: Patients accrued during 2010 and 2011 were treated according to standard protocols for disease stage. We analyzed selected biomarkers for predictive patterns of clinical response. Survival outcomes were calculated using Kaplan-Meier curves. Results: Baseline LDH was negatively correlated with length of survival and positively correlated to baseline VEGF in stage IV melanoma patients. We found a positive correlation between peripheral blood Treg concentrations and baseline VEGF in stage IV patients. No stage III patients died during the study period; median survival for stage IV patients was 48 months using a Kaplan-Meier survival curve, which illustrates the enrichment for exceptional stage IV survivors. Six stage IV patients remain disease free, including 4 of the 10 patients who received IL-2 +/− metastatectomy. Conclusions: Recent advances in immunotherapy have demonstrated durable therapeutic responses which may favorably impact survival. Examining T-cell characteristics of metastatic melanoma patients may gain further insight into underlying immunomodulation mechanisms to guide improved therapies.",
keywords = "Biomarkers, CD4+/CD8+ ratio, LDH, Melanoma, Stage IV, TH1/TH2 ratio, Tregs, VEGF",
author = "Agostino, {Nicole Marie} and Christine Saraceni and Hope Kincaid and Wenjing Shi and Nevala, {Wendy Kay} and Markovic, {Svetomir Nenad} and Nair, {Suresh G.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1186/s40064-015-0951-5",
language = "English (US)",
volume = "4",
journal = "SpringerPlus",
issn = "2193-1801",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

TY - JOUR

T1 - A prospective evaluation of the role of Vascular Endothelial Growth Factor (VEGF) and the immune system in stage III/IV melanoma

AU - Agostino, Nicole Marie

AU - Saraceni, Christine

AU - Kincaid, Hope

AU - Shi, Wenjing

AU - Nevala, Wendy Kay

AU - Markovic, Svetomir Nenad

AU - Nair, Suresh G.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background: The immune system and vascular endothelial growth factor (VEGF) may be influential in melanoma behavior. We performed a prospective, exploratory analysis in 10 stage III and 22 stage IV melanoma patients to observe factors influencing outcomes. Patients and methods: Patients accrued during 2010 and 2011 were treated according to standard protocols for disease stage. We analyzed selected biomarkers for predictive patterns of clinical response. Survival outcomes were calculated using Kaplan-Meier curves. Results: Baseline LDH was negatively correlated with length of survival and positively correlated to baseline VEGF in stage IV melanoma patients. We found a positive correlation between peripheral blood Treg concentrations and baseline VEGF in stage IV patients. No stage III patients died during the study period; median survival for stage IV patients was 48 months using a Kaplan-Meier survival curve, which illustrates the enrichment for exceptional stage IV survivors. Six stage IV patients remain disease free, including 4 of the 10 patients who received IL-2 +/− metastatectomy. Conclusions: Recent advances in immunotherapy have demonstrated durable therapeutic responses which may favorably impact survival. Examining T-cell characteristics of metastatic melanoma patients may gain further insight into underlying immunomodulation mechanisms to guide improved therapies.

AB - Background: The immune system and vascular endothelial growth factor (VEGF) may be influential in melanoma behavior. We performed a prospective, exploratory analysis in 10 stage III and 22 stage IV melanoma patients to observe factors influencing outcomes. Patients and methods: Patients accrued during 2010 and 2011 were treated according to standard protocols for disease stage. We analyzed selected biomarkers for predictive patterns of clinical response. Survival outcomes were calculated using Kaplan-Meier curves. Results: Baseline LDH was negatively correlated with length of survival and positively correlated to baseline VEGF in stage IV melanoma patients. We found a positive correlation between peripheral blood Treg concentrations and baseline VEGF in stage IV patients. No stage III patients died during the study period; median survival for stage IV patients was 48 months using a Kaplan-Meier survival curve, which illustrates the enrichment for exceptional stage IV survivors. Six stage IV patients remain disease free, including 4 of the 10 patients who received IL-2 +/− metastatectomy. Conclusions: Recent advances in immunotherapy have demonstrated durable therapeutic responses which may favorably impact survival. Examining T-cell characteristics of metastatic melanoma patients may gain further insight into underlying immunomodulation mechanisms to guide improved therapies.

KW - Biomarkers

KW - CD4+/CD8+ ratio

KW - LDH

KW - Melanoma

KW - Stage IV

KW - TH1/TH2 ratio

KW - Tregs

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84928668108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928668108&partnerID=8YFLogxK

U2 - 10.1186/s40064-015-0951-5

DO - 10.1186/s40064-015-0951-5

M3 - Article

VL - 4

JO - SpringerPlus

JF - SpringerPlus

SN - 2193-1801

IS - 1

ER -